Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT – Get Rating) – Oppenheimer equity researchers dropped their second-quarter 2022 earnings per share (EPS) estimates for Opiant Pharmaceuticals shares in a report released Wednesday, 11 may. Oppenheimer analyst L. Gershell now expects the tech company to post earnings per share of ($0.85) for the quarter, down from its previous forecast of ($0.36). $). Oppenheimer also released estimates of Opiant Pharmaceuticals’ Q3 2022 earnings at ($0.79) EPS, Q4 2022 earnings at ($0.93) EPS, and full-year 2022 earnings at ($4.54) $) EPS.
Other research analysts have also recently published research reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on Opiant Pharmaceuticals shares in a Wednesday, March 16 research report. TheStreet reduced shares of Opiant Pharmaceuticals from a “b-” rating to a “c” rating in a Monday, April 18 research report.
NASDAQ:OPNT shares opened at $12.47 on Monday. Opiant Pharmaceuticals has a fifty-two week low of $7.34 and a fifty-two week high of $37.71. The company has a quick ratio of 10.10, a current ratio of 8.72 and a debt ratio of 0.35. The company has a market capitalization of $63.35 million, a PE ratio of -8.60 and a beta of 0.65. The company has a 50-day simple moving average of $21.16 and a 200-day simple moving average of $25.91.
Opiant Pharmaceuticals (NASDAQ:OPNT – Get Rating) last reported quarterly earnings data on Tuesday, May 10. The technology company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimate of ($0.75) by ($1.68). Opiant Pharmaceuticals had a negative net margin of 13.70% and a negative return on equity of 15.28%. The company posted revenue of $4.47 million for the quarter, versus a consensus estimate of $7.13 million. During the same period of the previous year, the company achieved EPS of ($0.66).
Major investors have recently changed their stake in the company. Dorsey Wright & Associates acquired a new equity stake in Opiant Pharmaceuticals in Q4 worth approximately $72,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Opiant Pharmaceuticals in Q4 worth approximately $108,000. Advisor Group Holdings Inc. increased its stake in shares of Opiant Pharmaceuticals by 102.4% in Q3. Advisor Group Holdings Inc. now owns 6,325 shares of the technology company worth $163,000 after acquiring 3,200 additional shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Opiant Pharmaceuticals in Q4 worth approximately $216,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Opiant Pharmaceuticals by 481.8% in the 4th quarter. JPMorgan Chase & Co. now owns 6,743 shares of the technology company worth $227,000 after acquiring 5,584 additional shares during the period. 27.93% of the shares are held by institutional investors.
Opiant Pharmaceuticals Company Profile (Get a rating)
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops drugs for addiction and overdose. The company offers NARCAN Nasal Spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes drugs for the treatment of opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
Get news and reviews for Opiant Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.